Touch Medical Media coverage of data presented at EADV 2022:
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how well the primary and secondary outcome measures were achieved.
The abstract ‘Efficacy and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From a Phase 3, Randomized, Double Blind, Placebo-Controlled Study.’ ( Presentation ID D1T01.3E) was presented at EADV 2022, 7-10 September, 2022.
Questions
- What were the aims, design and eligibility criteria of the study you are presenting? (0:26)
- What were the primary and secondary outcome measures and how well were they achieved at 16 weeks? (2:13)
- What are the clinical implications of these findings? (3:25)
Disclosures: Loretta Fiorillo discloses receiving grant/ research support from Amgen, Pfizer, Galderma, Leo, and Timber; and serving on advisory boards for Amgen, Pfizer, Galderma, Leo, and Timber.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
